HC Wainwright Issues Positive Estimate for FATE Earnings

Key Points

• HC Wainwright raised its Q1 2026 EPS estimate for Fate to ($0.28) from ($0.30) and reiterated a Buy rating with a $7.00 price target, while projecting FY2026 EPS of ($1.17).
• Market sentiment is mixed: Weiss Ratings downgraded the stock to a "sell (e+)," and analysts overall have an average rating of Hold with an average target price of $4.50 (3 Buy, 4 Hold, 1 Sell).
• Shares jumped about 31.1% to open at $2.36 (a one‑year high), as Fate reported Q4 EPS of ($0.27) that matched estimates and quarterly revenue of $1.37 million; market cap is roughly $274 million.

Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - HC Wainwright upped their Q1 2026 earnings per share (EPS) estimates for Fate Therapeutics in a research report issued on Monday, May 4th. HC Wainwright analyst R. Burns now expects that the biopharmaceutical company will earn ($0.28) per share for the quarter, up from their previous forecast of ($0.30). HC Wainwright currently has a "Buy" rating and a $7.00 target price on the stock. The consensus estimate for Fate Therapeutics' current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for Fate Therapeutics' Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.31) EPS and FY2026 earnings at ($1.17) EPS.

Separately, Weiss Ratings lowered shares of Fate Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday, April 29th. Three research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Fate Therapeutics has an average rating of "Hold" and an average target price of $4.50.

Fate Therapeutics Trading Up 31.1%

FATE stock opened at $2.36 on Wednesday. Fate Therapeutics has a one year low of $0.91 and a one year high of $2.36. The firm has a 50-day moving average of $1.31 and a two-hundred day moving average of $1.21. The firm has a market capitalization of $274.42 million, a PE ratio of -2.05 and a beta of 2.13.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.27). The firm had revenue of $1.37 million for the quarter, compared to analysts' expectations of $1.20 million. Fate Therapeutics had a negative return on equity of 55.02% and a negative net margin of 2,051.08%.

Hedge Funds Weigh In On Fate Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of FATE. Commonwealth Equity Services LLC purchased a new stake in shares of Fate Therapeutics in the fourth quarter worth approximately $26,000. Bridgeway Capital Management LLC acquired a new stake in shares of Fate Therapeutics during the second quarter worth approximately $28,000. Corient Private Wealth LLC purchased a new position in Fate Therapeutics during the fourth quarter valued at approximately $29,000. The Manufacturers Life Insurance Company acquired a new position in Fate Therapeutics in the 4th quarter valued at approximately $35,000. Finally, Russell Investments Group Ltd. lifted its position in Fate Therapeutics by 73.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 28,676 shares of the biopharmaceutical company's stock worth $36,000 after buying an additional 12,114 shares in the last quarter. Hedge funds and other institutional investors own 97.54% of the company's stock.

About Fate Therapeutics

Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate's research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.

Central to Fate's pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.